Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.09. | Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 61 | GlobeNewswire (Europe) | MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
16.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
09.09. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
08.09. | Pasithea advances to second dose cohort in NF1 clinical trial | 4 | Investing.com | ||
08.09. | Pasithea: NF1-Studie erreicht nach positiver Sicherheitsprüfung die nächste Dosierungsstufe | 1 | Investing.com Deutsch | ||
08.09. | Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 111 | GlobeNewswire (Europe) | -- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
03.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.08. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
31.07. | Pasithea completes enrollment of first cohort in NF1 clinical trial | 7 | Investing.com | ||
31.07. | Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 410 | GlobeNewswire (Europe) | MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
11.07. | Pasithea Therapeutics terminiert Hauptversammlung für den 3. September 2025 | 2 | Investing.com Deutsch | ||
11.07. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | Pasithea Therapeutics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
11.06. | Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
02.06. | Pasithea reports promising phase 1 results for cancer drug | 2 | Investing.com | ||
02.06. | Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 | 240 | GlobeNewswire (Europe) | -- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated... ► Artikel lesen | |
20.05. | Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model | - | RTTNews | ||
20.05. | Pasithea's PAS-004 shows promise in inflammatory disease study | 1 | Investing.com | ||
20.05. | PAS-004 von Pasithea zeigt vielversprechende Ergebnisse in Studie zu Entzündungskrankheiten | 1 | Investing.com Deutsch | ||
20.05. | Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases | 3 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
OCUGEN | 1,164 | -1,56 % | Forecasting The Future: 4 Analyst Projections For Ocugen | ||
GENPREX | 1,820 | -100,00 % | Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025 | AUSTIN, TX / ACCESS Newswire / September 10, 2025 / Genprex, Inc.'s President and Chief Executive Officer, Ryan Confer, will present at the Investor Summit Virtual on September 16, 2025, offering investors... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,100 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
89BIO | 14,870 | +0,07 % | Roche kauft amerikanische 89bio für bis zu 3,5 Milliarden Dollar | BASEL (dpa-AFX) - Roche übernimmt für bis zu 3,5 Milliarden US-Dollar die amerikanische 89bio. Das Biopharma-Unternehmen leistet laut Roche Pionierarbeit bei der Entwicklung innovativer Therapien zur... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,440 | +2,44 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
MBX BIOSCIENCES | 20,000 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension | Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in... ► Artikel lesen | |
NUVALENT | 78,90 | 0,00 % | Nuvalent schließt FDA-Zulassungsantrag für Lungenkrebsmedikament Zidesamtinib ab | ||
QIAGEN | 38,980 | -0,06 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 38,780 | -1,32 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
BIONTECH | 83,40 | -0,24 % | PAUKENSCHLÄGE bei Megatrend-Aktien: Rheinmetall, BioNTech, First Hydrogen | Rheinmetall gibt Vollgas: zu Land, zu Wasser, in der Luft und im Weltraum. Jüngster Paukenschlag ist die angekündigte Übernahme der Marinesparte von Lürssen. Ist das der Rückenwind für die Aktie, um... ► Artikel lesen | |
IMMUNOVANT | 15,590 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 17,375 | +0,09 % | Arcutis Biotherapeutics, Inc.: Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress | ||
EVOTEC | 6,330 | +0,92 % | EQS-DD: Evotec SE: Paul Hitchin, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
16.09.2025 / 12:06... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,980 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances | ||
TOURMALINE BIO | 47,750 | +0,04 % | Tourmaline Bio To Be Acquired By Novartis; Was TRML Stock In Your Investment Portfolio? | BASEL (dpa-AFX) - Tourmaline Bio Inc. (TRML), a late-stage clinical biotechnology company developing medicines for life-altering inflammatory and immune diseases, is all set to be acquired by... ► Artikel lesen |